Patent ID: 11912775
Assignee: KYOWA KIRIN CO., LTD.
Field: Measurement (Instruments)
Classification: CPC C  A  G | IPC A  C  G

Claim 15:
16. A derivative of an antibody, comprising:
a radioisotope, a low molecular drug, a high molecular drug, a protein, or an antibody drug bound to the monoclonal antibody or an antibody fragment thereof according to claim 1,
wherein the low molecular drug is at least one selected from the group consisting of amifostine (Ethyol), cisplatin, dacarbazine (DTIC), dactinomycin, mechlorethamine (nitrogen mustard), streptozocin, cyclophosphamide, ifosfamide, carmustine (BCNU), lomustine (CCNU), doxorubicin (Adriamycin), epirubicin, gemcitabine (Gemzar), daunorubicin, procarbazine, mitomycin, cytarabine, etoposide, methotrexate, fluorouracil, vinblastine, vincristine, bleomycin, daunomycin, peplomycin, estramustine, paclitaxel (Taxol), docetaxel (Taxotere), Aldesleukin, asparaginase, busulfan, carboplatin, oxaliplatin, nedaplatin, cladribine, camptothecin, 7-ethyl-10-hydroxycamptothecin (SN38), floxuridine, fludarabine, hydroxyurea, idarubicin, mesna, irinotecan (CPT-11), nogitecan, mitoxantrone, topotecan, leuprolide, megestrol, melphalan, mercaptopurine, plicamycin, mitotane, pegaspargase, pentostatin, pipobroman, tamoxifen, goserelin, leuprorelin, flutamide, teniposide, testolactone, thioguanine, thiotepa, uracil mustard, vinorelbine, chlorambucil, prednisolone, methylprednisolone, vindesine, nimustine, semustine, capecitabine, Tomudex, azacitidine, UFT, oxaloplatin, gefitinib (Iressa), imatinib (STI571), erlotinib, FMS-like tyrosine kinase 3 (Flt3) inhibitor, vascular endothelial growth factor receptor (VEGFR) inhibitor, fibroblast growth factor receptor (FGFR) inhibitor, epidermal growth factor receptor (EGFR) inhibitor, radicicol, 17-allylamino-17-demethoxygeldanamycin, rapamycin, amsacrine, all-trans retinoic acid, thalidomide, lenalidomide, anastrozole, fadrozole, letrozole, exemestane, gold thiomalate, bucillamine, azathioprine, mizoribine, cyclosporine, hydrocortisone, bexarotene (Targretin), dexamethasone, progestins, estrogens, anastrozole (Arimidex), Aspirin, indomethacin, celecoxib, penicillamine, chlorpheniramine maleate, chloropheniramine, clemastine, tretinoin, arsenic, bortezomib, allopurinol, calicheamicin, ibritumomab tiuxetan, targretin, ozogamine, clarithromycin, leucovorin, ketoconazole, aminoglutethimide, suramin, or maytansinoid and derivatives thereof, and
wherein the high molecular drug is at least one selected from the group consisting of polyethylene glycol, albumin, dextran, polyoxyethylene, a styrene maleic acid copolymer, polyvinyl pyrrolidone, a pyran copolymer, and hydroxypropyl methacrylamide.